CN110582491A - Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 - Google Patents

Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 Download PDF

Info

Publication number
CN110582491A
CN110582491A CN201780090153.1A CN201780090153A CN110582491A CN 110582491 A CN110582491 A CN 110582491A CN 201780090153 A CN201780090153 A CN 201780090153A CN 110582491 A CN110582491 A CN 110582491A
Authority
CN
China
Prior art keywords
compound
ring
cancer
group
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780090153.1A
Other languages
English (en)
Other versions
CN110582491B (zh
Inventor
赵焰平
王红军
李功
姜媛媛
李想
周丽莹
刘亚男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitralign Inc
Original Assignee
Mitralign Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitralign Inc filed Critical Mitralign Inc
Publication of CN110582491A publication Critical patent/CN110582491A/zh
Application granted granted Critical
Publication of CN110582491B publication Critical patent/CN110582491B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201780090153.1A 2017-06-30 2017-09-29 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 Active CN110582491B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/091086 2017-06-30
CNPCT/CN2017/091086 2017-06-30
PCT/CN2017/104294 WO2019000683A1 (zh) 2017-06-30 2017-09-29 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN110582491A true CN110582491A (zh) 2019-12-17
CN110582491B CN110582491B (zh) 2023-09-29

Family

ID=59997267

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780090153.1A Active CN110582491B (zh) 2017-06-30 2017-09-29 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途

Country Status (6)

Country Link
US (1) US10323023B2 (zh)
EP (1) EP3421464B1 (zh)
JP (1) JP7039802B2 (zh)
KR (1) KR102469161B1 (zh)
CN (1) CN110582491B (zh)
WO (1) WO2019000683A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116251104A (zh) * 2022-12-30 2023-06-13 中山大学附属第一医院 Kd025在制备用于治疗骨关节炎药物中的应用
WO2023202642A1 (zh) * 2022-04-20 2023-10-26 上海挚盟医药科技有限公司 Rho相关蛋白激酶抑制剂及其制备和应用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102585860B1 (ko) * 2017-06-30 2023-10-06 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Ｒｈｏ-관련 단백질 키나아제 억제제, 이를 포함하는 약학 조성물, 및 이의 제조 방법 및 용도
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
JPWO2021193982A1 (zh) * 2020-03-27 2021-09-30
JP2023525047A (ja) 2020-05-06 2023-06-14 エイジャックス セラピューティクス， インコーポレイテッド Ｊａｋ２阻害薬としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール
US20230257376A1 (en) * 2020-07-14 2023-08-17 Wuhan Ll Science And Technology Development Co., Ltd. Rock inhibitor, and preparation method therefor and use thereof
BR112023001049A2 (pt) * 2020-07-22 2023-03-07 Beijing Tide Pharmaceutical Co Ltd Método para tratamento de doença de enxerto versus hospedeiro causada por transplante de célula-tronco hematopoiética
EP4225742A1 (en) 2020-10-05 2023-08-16 Enliven Therapeutics, Inc. 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases
WO2022140527A1 (en) 2020-12-23 2022-06-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
TW202334139A (zh) 2021-11-09 2023-09-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳氧基苯并咪唑及氮雜苯并咪唑
CA3238675A1 (en) * 2021-11-16 2023-05-25 Beijing Tide Pharmaceutical Co., Ltd. Nanocrystalline preparation of rock2 inhibitor and preparation method therefor
CN114504574B (zh) * 2021-12-30 2023-05-09 北京鑫开元医药科技有限公司 一种2-((2-甲氧基苯基)磺酰基)异吲哚啉类化合物药物制剂及其制备方法
CN113980003B (zh) * 2021-12-30 2022-05-20 北京鑫开元医药科技有限公司 一种2-((2-甲氧基苯基)磺酰基)异吲哚啉类化合物及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120202793A1 (en) * 2009-03-09 2012-08-09 Paul Sweetnam Rho kinase inhibitors
CN104903320A (zh) * 2013-01-11 2015-09-09 富士胶片株式会社 含氮杂环化合物或其盐
CN105120869A (zh) * 2012-10-05 2015-12-02 卡德门企业有限公司 眼部病症的治疗
CN106478651A (zh) * 2015-08-31 2017-03-08 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2253266T3 (es) 1999-11-30 2006-06-01 Pfizer Products Inc. Compuestos de 2,4-diaminopirimidina utiles como inmunosupresores.
EP1317448B2 (en) 2000-09-15 2011-05-04 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DE60120219T2 (de) 2000-12-21 2007-04-12 Vertex Pharmaceuticals Inc., Cambridge Pyrazolverbindungen als protein-kinase-inhibitoren
ATE325795T1 (de) 2001-03-23 2006-06-15 Bayer Corp Rho-kinase inhibitoren
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
ES2305435T3 (es) 2002-01-10 2008-11-01 Bayer Healthcare Ag Inhibidores de la rho-quinasa.
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
ATE527250T1 (de) 2002-11-21 2011-10-15 Novartis Ag 2,4,6-trisubstituierten pyrimidinen als phosphotidylinositol (pi) 3-kinase inhibitoren und deren verwendung zur behandlung von krebs
WO2006135383A2 (en) 2004-08-04 2006-12-21 Myriad Genetics, Inc. Indazoles
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
MX2007014619A (es) 2005-05-20 2009-02-13 Vertex Pharma Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
WO2007076161A2 (en) 2005-12-27 2007-07-05 Myriad Genetics, Inc Compounds with therapeutic activity
WO2008054599A2 (en) 2006-09-27 2008-05-08 Surface Logix, Inc. Rho kinase inhibitors
WO2012040499A2 (en) 2010-09-22 2012-03-29 Surface Logix, Inc. Metabolic inhibitors
EP2433636A1 (en) 2010-09-27 2012-03-28 Medizinische Universität Wien Treatment of Malignant Diseases
US9096579B2 (en) 2012-04-20 2015-08-04 Boehringer Ingelheim International Gmbh Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments
CN105102456B (zh) 2012-09-28 2017-11-14 癌症研究技术有限公司 非典型蛋白激酶c的氮杂喹唑啉抑制剂
JP6507157B2 (ja) 2013-10-07 2019-04-24 カドモン コーポレイション，リミティド ライアビリティ カンパニー Ｒｈｏキナーゼ阻害剤
WO2015157556A1 (en) 2014-04-09 2015-10-15 Kadmon Corporation, Llc Treatment of gvhd
US9902702B2 (en) 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
MA40957A (fr) 2014-10-09 2017-09-19 Biomarin Pharm Inc Inhibiteurs de biosynthèse d'héparane sulfate pour traiter des maladies
WO2016138335A1 (en) 2015-02-27 2016-09-01 Lycera Corporation Indazolyl thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease
EP3283479B1 (en) 2015-04-01 2022-12-14 Rigel Pharmaceuticals, Inc. Tgf-beta inhibitors
EP3313825A4 (en) 2015-06-26 2019-03-13 Kadmon Corporation, LLC GLUCOSE ABSORPTION INHIBITORS
US10729691B2 (en) 2015-06-26 2020-08-04 Kadmon Corporation, Llc Treatment of infectious diseases with glucose uptake inhibitors
EP3349579A4 (en) * 2015-09-17 2019-03-20 Sunshine Lake Pharma Co., Ltd. SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE
EP4067347B1 (en) 2016-05-24 2024-06-19 Genentech, Inc. Heterocyclic inhibitors of cbp/ep300 for the treatment of cancer
WO2018039539A1 (en) 2016-08-26 2018-03-01 Lycera Corporation Indazolyl-l,2,4-thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease
EP3421465B1 (en) 2017-06-30 2022-10-26 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
KR102585860B1 (ko) 2017-06-30 2023-10-06 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Ｒｈｏ-관련 단백질 키나아제 억제제, 이를 포함하는 약학 조성물, 및 이의 제조 방법 및 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120202793A1 (en) * 2009-03-09 2012-08-09 Paul Sweetnam Rho kinase inhibitors
CN105120869A (zh) * 2012-10-05 2015-12-02 卡德门企业有限公司 眼部病症的治疗
CN104903320A (zh) * 2013-01-11 2015-09-09 富士胶片株式会社 含氮杂环化合物或其盐
CN106478651A (zh) * 2015-08-31 2017-03-08 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023202642A1 (zh) * 2022-04-20 2023-10-26 上海挚盟医药科技有限公司 Rho相关蛋白激酶抑制剂及其制备和应用
CN116251104A (zh) * 2022-12-30 2023-06-13 中山大学附属第一医院 Kd025在制备用于治疗骨关节炎药物中的应用

Also Published As

Publication number Publication date
US10323023B2 (en) 2019-06-18
US20190002442A1 (en) 2019-01-03
KR102469161B1 (ko) 2022-11-23
EP3421464B1 (en) 2021-11-24
CN110582491B (zh) 2023-09-29
JP2020525523A (ja) 2020-08-27
KR20200024777A (ko) 2020-03-09
JP7039802B2 (ja) 2022-03-23
WO2019000683A1 (zh) 2019-01-03
EP3421464A1 (en) 2019-01-02

Similar Documents

Publication Publication Date Title
CN111217797B (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
CN110582491A (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
CN110573501A (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
EP2945623B1 (en) Hedgehog pathway signaling inhibitors and therapeutic applications thereof
WO2018157856A1 (zh) 酰胺类衍生物抑制剂及其制备方法和应用
CN110655503A (zh) 取代的三唑类化合物、包含其的药物组合物、其制备方法及其用途
TWI585087B (zh) Novel tetrahydropyridine pyrimidine compounds or salts thereof
TW201348213A (zh) 喹唑啉二酮衍生物
WO2022199662A1 (zh) 一种多环化合物及其应用
TW201917129A (zh) 含吡唑基的三并環類衍生物、其製備方法和應用
WO2023045960A1 (zh) 一种吡啶类衍生物及其用途
CN112969694B (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其用途
WO2023165581A1 (zh) 一种吡啶类衍生物及其用途
EP4219453A1 (en) Pyrazole compound and preparation method therefor and use thereof
CN113166109A (zh) 氨基吡啶类化合物及其制备方法和用途
WO2023165574A1 (zh) 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
CN111377906B (zh) 取代的吡嗪化合物及其制备方法和用途
WO2024160058A1 (zh) 草酸二酰胺化合物、包含其的药物组合物及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant